Type 1 11 &bgr;-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?

Publisher： Bentham Science Publishers

E-ISSN： 2212-3873|6|3|259-269

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.6, Iss.3, 2006-09, pp. : 259-269

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

By Fotsch Christopher   Askew Ben C   Chen Jian Jeffrey  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 3, 2005-03 ,pp. : 289-303

Informa Healthcare

Access to resources Recommend Favorite

11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease

By Walker Brian R   Seckl Jonathan R  

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 6, 2003-12 ,pp. : 771-783

Informa Healthcare

Access to resources Recommend Favorite

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome – 11β-hydroxysteroid dehydrogenase type 1

By Stewart Paul M  

Clinical Medicine, Vol. 5, Iss. 2, 2005-03 ,pp. : 142-146

Royal College Of Physicians

Access to resources Recommend Favorite

Design, Synthesis and In Vitro Evaluation of 4-Androstene-3,17-dione/Adenosine Hybrid Compounds as Bisubstrate Inhibitors of Type 3 17&bgr;-Hydroxysteroid Dehydrogenase

By  

Medicinal Chemistry, Vol. 2, Iss. 4, 2006-01 ,pp. : 329-347

Bentham Science Publishers

Access to resources Recommend Favorite

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

By Webster Scott Peter   Pallin Thomas David  

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 12, 2007-12 ,pp. : 1407-1422

Informa Healthcare

Access to resources Recommend Favorite